Justin Taylor, MD, discusses the rationale for an ongoing phase II trial that is exploring the combination of vemurafenib, a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab in previously untreated patients with classical hairy cell leukemia.
Justin Taylor, MD, attending physician at Memorial Sloan Kettering Cancer Center (MSKCC), discusses the rationale for an ongoing phase II trial (NCT03410875) that is exploring the combination of vemurafenib (Zelboraf), a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) in previously untreated patients with classical hairy cell leukemia.
This is the first trial to look at targeted therapies in the frontline for treatment of patients with hairy cell leukemia, Taylor says. At MSKCC and the University of Perugia in Italy, vemurafenib was evaluated in a phase II study in the relapsed setting for this patient population. The data from that trial suggested good response rates with the targeted agent, Taylor explains, which led to the rationale for this ongoing trial.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More